<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02540460</url>
  </required_header>
  <id_info>
    <org_study_id>LCB01-0371-14-1-01</org_study_id>
    <nct_id>NCT02540460</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371</brief_title>
  <official_title>A Phase I Clinical Study, Multiple Dose of LCB01-0371 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LegoChem Biosciences, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LegoChem Biosciences, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the population pharmacokinetics of LCB01-0371
      after a multiple oral dose in healthy male subjects.

      To investigate safety, tolerability of LCB01-0371 after a multiple oral dose in healthy male
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Double blind, randomized, placebo control, multiple dose, dose escalation study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No of Adverse events</measure>
    <time_frame>From date of randomization until follow up after 3 days from last hospital discharge</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Cmax(Peak plasma concentration)</measure>
    <time_frame>0(predose), 0.5, 1, 2, 4, 8 and 12hours</time_frame>
    <description>Predose date: 1, 3, 6, 9, 12, 15, 17, 19, 20 and 21Days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: AUC(Area under the curve)</measure>
    <time_frame>0(predose), 0.5, 1, 2, 4, 8 and 12hours</time_frame>
    <description>Predose date: 1, 3, 6, 9, 12, 15, 17, 19, 20 and 21Days</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCB01-0371 800mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 800mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LCB01-0371 1200mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCB01-0371 1200mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>LCB01-0371 800mg, LCB01-0371 800mg BID, LCB01-0371 1200mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg</intervention_name>
    <description>LCB01-0371 800mg</description>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 800mg BID</intervention_name>
    <description>LCB01-0371 800mg BID</description>
    <arm_group_label>LCB01-0371 800mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCB01-0371 1200mg BID</intervention_name>
    <description>LCB01-0371 1200mg BID</description>
    <arm_group_label>LCB01-0371 1200mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>LCB01-0371 800mg</arm_group_label>
    <arm_group_label>LCB01-0371 800mg BID</arm_group_label>
    <arm_group_label>LCB01-0371 1200mg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male between 20 and 45 years of age at the time of screening

          2. Subjects with body mass index (BMI) between 20 kg/m2 and 27 kg/m2 at the time of
             screening

          3. Agree to continue to use a medically reliable dual contraception and not to donate
             sperm until 30th days after study completion

          4. Capable of giving written informed consent, willing to participate in this clinical
             trial, and willing to comply with all study requirements.

        Exclusion Criteria:

          1. History of liver, kidney, alimentary, respiratory, musculoskeletal, endocrine,
             neuropsychiatric, hemato-oncologic, cardiovascular problem(s)

          2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer)
             within 6 months possibly affecting absorption of clinical trial drugs, or history of
             surgery (except simple appendectomy and herniotomy)

          3. History of hypersensitivity reaction or history of clinically significant
             hypersensitivity reaction to LCB01-0371 or same class of the study drugs (linezolid)
             or other drugs including aspirin and antibiotics

          4. History of drug abuse or positive result at urine drug screening

          5. AST, ALT, r-GT, bilirubin(total) values over than 1.5 times of ULN
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young Lag Cho, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Legochembioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Bundang</city>
        <state>Gyeonggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>September 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2015</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

